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AbstrACt
Objectives National and international guidelines 
recommend prompt referral of patients presenting with 
inflammatory arthritis (IA), but general practitioners (GPs) 
feel uncertain in their proficiency to detect synovitis 
through joint examination, the method of choice to identify 
IA. Our objective was to develop and validate a rule 
composed of clinical characteristics to assist GPs and 
other physicians in identifying IA when in doubt.
Design Split-sample derivation and validation study.
setting The Leiden Early Arthritis Recognition Clinic 
(EARC), a screening clinic for patients in whom GPs 
suspected but were unsure of the presence of IA.
Participants 1288 consecutive patients visiting the EARC.
Primary and secondary outcome 
measures Associations of clinical characteristics with 
presence of IA were determined using logistic regression 
in 644 patients, while validating the results in the other 
644 patients (split-sample validation). To facilitate 
application in clinical practice, a simplified rule (with 
scores ranging from 0 to 7.5) was derived and validated.
results IA was identified by a rheumatologist in 41% of 
patients. In univariable analysis, male gender, age ≥60 
years, symptom duration <6 weeks, morning stiffness 
>60 min, a low number of painful joints (1–3 joints), 
presence of patient-reported joint swelling and difficulty 
with making a fist were associated with IA in the derivation 
data set. Using multivariable analysis, a simplified rule 
consisting of these seven items was derived and validated, 
yielding an area under the receiver operator characteristic 
curve (AUC) of 0.74 (95% CI 0.70 to 0.78) in the derivation 
data set. Validation yielded an AUC of 0.71 (95% CI 0.67 to 
0.75). Finally, the model was repeated to study predicted 
probabilities with a lower prevalence of inflammatory 
arthritis to simulate performance in primary care settings.
Conclusions Our rule, composed of clinical parameters, 
had reasonable discriminative ability for IA and could 
assist physicians in decision-making in patients with 
suspected IA, increasing appropriateness of healthcare 
utilisation.
bACkgrOunD 
Early initiation of disease modifying anti-
rheumatic drugs is strongly associated with 
improved outcomes of rheumatoid arthritis 
(RA).1 National and international guidelines 
attempt to facilitate this by emphasising 
prompt referral of patients presenting with 
inflammatory arthritis (IA) to a rheumatolo-
gist. The European League Against Rheuma-
tism taskforce for the management of early IA 
recommends referral within 6 weeks of onset 
of symptoms,2 while in the UK, the National 
Institute for Health and Care Excellence 
(NICE) guidelines advises referral to a rheu-
matologist in patients with new, persistent 
(>3–4 weeks) synovitis within 3 working days.3 
However, it was demonstrated that this referral 
timeline is achieved in only 17% of patients.4 
On average, patients with RA are seen four 
(and sometimes more than eight) times by 
general practitioners (GPs) before they refer 
to secondary care,5–8 which may reflect the 
difficulty of differentiating patients with early 
IA from patients with other types of common 
musculoskeletal symptoms. A recent qualita-
tive study revealed that GPs acknowledge the 
importance of early detection and referral, 
but feel uncertain in their proficiency to 
detect synovitis through joint examination, 
the method of choice to identify IA.2 9 As a 
consequence, the referral to a rheumatologist 
strengths and limitations of this study
 ► A clinical rule could help to select patients to refer 
for additional investigations (laboratory or imaging) 
or to secondary care. This could promote early iden-
tification of inflammatory arthritis and increase ap-
propriateness of healthcare utilisation.
 ► Data were collected prospectively in a population of 
patients in which general practitioners had doubt on 
the presence of inflammatory arthritis.
 ► The main limitation is that data were not collected 
in primary care itself, but in a setting intermediary 
between primary and secondary care. Further ex-
ternal validation in general practitioner settings is 
therefore required.
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may be delayed, which contributes to overall treatment 
delay in early RA, as observed in Europe.10 11 
This is further complicated by the high incidence of 
consultations for various common musculoskeletal symp-
toms and the low incidence of early IA in primary care.12 
The consultation prevalence of any musculoskeletal 
symptom in primary care in the UK approximates 2405 
per 10 000 per year,13 making it the most common organ 
system consulted for at GP practices.12–14 Although muscu-
loskeletal symptoms are common, GPs suspect IA (based 
on pattern recognition) in only a very small minority of 
patients.5 In these patients, GPs often lack confidence in 
joint assessment for synovitis.
To support early detection, several initiatives have been 
developed, including triage systems. The best studied 
triage system (the Early Inflammatory Arthritis Ques-
tionnaire) was developed and validated for patients 
attending secondary and tertiary care.15–17 Further-
more, several referral guidelines for GPs6 18–22 and public 
awareness campaigns have been developed, for instance, 
one attempting to simplify pattern recognition to the 
‘S-Factor’: Stiffness, Swelling, Squeezing. However, none 
of these initiatives were designed using primary care 
data, and all assume that GPs can differentiate between 
the presence and absence of joint swelling,6 18–20 which 
continues to be a barrier to the early detection of IA.
Altogether, there is a contradiction with the need to 
refer as quickly as possible while evidence who must be 
referred or, in line with this, in whom additional investi-
gations are appropriate is lacking. To solve the issue, we 
have developed and validated a rule composed of clinical 
characteristics, by taking advantage of data from a setting 
intermediate between primary and secondary care. This 
intermediate setting of an the Early Arthritis Recognition 
Clinic (EARC) was a local solution to promote early refer-
rals and is not easily implementable in other regions. The 
clinical rule derived from these data, however, is easy to 
apply and may assist in the decision-making process in 
patients with musculoskeletal symptoms with suspected 
IA at other places, in order to promote early identifica-
tion of IA.
MethODs
study population
To promote early recognition of early IA, EARC was initi-
ated in September 2010 in Leiden, the Netherlands. The 
outpatient clinic of the Department of Rheumatology of 
the Leiden University Medical Centre (LUMC) is the only 
referral centre in a healthcare region of ∼400 000 people. 
GPs were instructed to refer patients to EARC in whom 
they were unsure about the presence of IA (instead of a 
‘wait-and-see’ approach or performing additional tests). 
EARC system has reduced referral delay from 8 to 2 weeks, 
and improved early identification of IA.11 23 To emphasise 
the importance of early identification of IA and aiming 
to inform on the purpose of EARC, a region-wide educa-
tional campaign was conducted among regional GPs.
In addition to (and distinct from) EARC, the LUMC 
also has an Early Arthritis Clinic (EAC). EAC was estab-
lished in 1993 to include and follow patients with early 
arthritis and to offer the possibility of rapid access to 
rheumatology care, usually within a week of referral. To 
differentiate between the clinics, GPs were instructed to 
refer to EAC if there was a clear synovitis or very high 
suspicion of IA (ie, to continue as they had before, since 
there was no benefit for such patients to go to EARC first) 
and to refer to EARC when in doubt about the presence 
of IA (ie, to not ‘wait-and-see’ or order additional tests). 
Thus, patients included in this study represent the diffi-
cult group in whom GPs were uncertain of the presence 
of suspected IA; patients with a very high degree of suspi-
cion were referred directly to EAC.
EARC screening clinic was held twice a week between 
2010 and 2014 and once a week from 2014 onwards. After 
GP referral, patients can visit EARC without an appoint-
ment. All patients that visited EARC between 2010 and 
September 2015 were studied.
Data collection
At EARC, patients completed a short questionnaire about 
their joint symptoms, after which they were seen by an 
experienced rheumatologist (AvdHvM or other senior 
Table 1 Characteristics of patients visiting the Early 
Arthritis Recognition Clinic
Derivation
(n=644)
Validation 
(n=644) P values*
Male, n (%) 190 (30) 198 (31) 0.62
Age in years, mean±SD 52±16 51±17 0.27
Symptom duration in 
weeks, median (IQR)
10 (3–45) 12 (4–45) 0.18
Acute onset of 
symptoms†, n (%)
252 (39) 238 (37) 0.45
Symptoms worst in the 
early morning, n (%)
372 (58) 351 (55) 0.10
Morning stiffness in 
minutes, median (IQR)
10 (0–30) 10 (0–30) 0.33
Number of painful joints, 
median (IQR)
7 (2–15) 6 (3–15) 0.69
Number of patient-
reported swollen joints, 
median (IQR)
2 (1–5) 2 (1–5) 0.19
Difficulty with making a 
fist, n (%)
329 (51) 301 (47) 0.06
Arthritis present at 
joint examination 
by experienced 
rheumatologist, n (%)
271 (42) 252 (39) 0.28
*Unpaired t-tests, χ2 tests and Mann-Whitney U tests were used as 
appropriate.
†Patients were asked to define onset of symptoms; either 
acute onset of symptoms or gradual onset of symptoms, see 
online supplementary appendix S1. 
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rheumatologists) who performed a full 66-joint exam-
ination. If synovitis was determined by physical examina-
tion, patients were fast-tracked to visit EAC within 1 week 
for further evaluation and treatment. Patients without 
IA were discharged to primary care. The questionnaire 
completed by patients, provided in online supplementary 
appendix S1, contained questions on age, gender, date 
of symptom onset, date of first visit to GP, presence of a 
(sub)acute symptom onset (vs a gradual symptom-onset), 
morning stiffness (duration in minutes), which part of 
the day symptoms were worst and whether they had diffi-
culty with making a fist. Patients were asked to indicate 
on a 52-joint mannequin which joints were painful and 
which joints they considered to be swollen. IA, defined 
as synovitis confirmed by the rheumatologist at physical 
examination, was used as outcome.
Collected data were anonymised and entered in a 
research database at chronological order of visiting EARC. 
Derivation and validation of the model
We used half of the data set for derivation and the other 
half for validation of results (split-sample validation). To 
prevent bias by (unknown) effects of inclusion period, 
patients with odd ID numbers (1, 3, etc) were included in 
the derivation data set and those with even ID numbers 
(2, 4, etc) were used for validation.
To prevent exclusion of patients with one or more 
missing variables, we imputed missing values using 
chained equations24; frequencies of missing variables are 
presented in online supplementary appendix S2. The 
variables ‘difficulty with making a fist’ and ‘self-reported 
joint swelling’ were most frequently missing as these 
were added to the questionnaire after 1 April 2012, thus 
absence of these data was considered to occur completely 
at random.
We conducted logistic regression analysis modelling 
with presence of IA (defined as rheumatologist-confirmed 
synovitis on physical examination) as dependent variable. 
Continuous variables were categorised using clinically 
relevant cut-offs: age: <40/40–59.9/≥60 years; duration 
of symptoms: <6/6–11/12–51.9/≥52 weeks; duration of 
morning stiffness: ≤60/>60 min; number of painful joints: 
0/1–3/4–10/≥11; number of swollen joints: 0/1–3/4–
10/≥11. We performed univariable logistic regression to 
evaluate associations between dependent variables and 
Table 2 Univariable logistic regression in the derivation data set with presence of synovitis on joint examination as outcome
Arthritis (n=271) No arthritis (n=373) OR (95% CI)
Male, n (%) 104 (38) 86 (23) 2.1 (1.5 to 2.9)
Age, n (%) 
  <40 49 (18) 104 (28) (ref)
  40–59.9 109 (40) 172 (46) 1.3 (0.89 to 2.0)
  ≥60 113 (42) 97 (26) 2.5 (1.6 to 3.8)
Symptom duration in weeks, n (%) 
  <6 124 (46) 103 (28) 3.8 (2.4 to 5.9)
  6–11 38 (14) 62 (17) 1.9 (1.1 to 3.9)
  12–51.9 66 (24) 75 (20) 2.7 (1.7 to 4.5)
  ≥52 43 (16) 132 (36) (ref)
Acute onset of symptoms *, n (%) 122 (45) 131 (35) 1.5 (1.1 to 2.1)
Symptoms worst in early morning, n (%) 158 (58) 214 (57) 1.1 (0.69 to 1.6)
Morning stiffness > 60 min , n (%) 45 (17) 40 (11) 1.7 (1.03 to 2.7)
Number of painful joints, n (%) 
  0 1 (0) 10 (3) (ref)
  1–3 110 (41) 82 (22) 13.2 (1.7 to 105.5)
  4–10 76 (28) 123 (33) 6.1 (0.77 to 49.0)
  ≥11 84 (31) 158 (42) 5.2 (0.65 to 41.3)
Number of patient-reported swollen joints, n (%) 
  0 18 (7) 71 (19) (ref)
  1–3 115 (42) 119 (32) 3.7 (2.0 to 6.9)
  4–10 87 (32) 115 (31) 2.9 (1.5 to 5.5)
  ≥11 51 (19) 68 (18) 2.9 (1.4 to 5.9)
Difficulty with making a fist, n (%) 156 (58) 172 (46) 1.6 (1.1 to 2.4)
*Patients were asked to define onset of symptoms; either acute onset of symptoms or gradual onset of symptoms, see online supplementary 
appendix S1.
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presence of IA. Variables with p values <0.05 in univari-
able analyses were entered in multivariable regression 
analyses (enter model) to obtain a model with a small 
number of variables. If several categories within a vari-
able had similar regression coefficients in multivariable 
modelling, we pooled these categories and repeated the 
analysis. In subanalysis, we also performed a multivari-
able logistic regression model with the pooled categories 
using backward selection.
To obtain a simplified rule applicable in daily care, we 
rounded the regression coefficients of the final multivari-
able logistic regression model to the nearest 0.5 (irrespec-
tive of p value). This resulted in an easily calculable risk 
score. For each value of the risk score, we determined 
test characteristics (ie, sensitivity and specificity) and 
predicted probabilities of the presence of inflammatory 
arthritis.
We evaluated the overall discriminative ability of the 
models using the area under the receiver operating 
characteristic curve (AUC). The model’s calibration was 
assessed by generating a calibration plot to measure good-
ness of fit, where the data were partitioned in 10 equally 
sized groups based on the predicted probabilities using 
the final fitted multivariable model. In each group, the 
average predicted probability on current IA was compared 
with the observed prevalence, both in the derivation and 
validation data set. Additionally, the Hosmer-Lemeshow 
statistic was calculated.
To estimate performance of our simplified rule in 
a setting with a different prevalence of IA (eg, primary 
care), a simulation was performed. Accurate data on prev-
alence of IA in GP practices are lacking, and therefore an 
estimation was made based on previous literature. One 
study revealed that 27% assigned with the International 
Classification of Primary Care-1 code for suspected IA in 
their medical record had confirmed RA (n=38), polyar-
thritis (n=5) or oligoarthritis (n=8) following rheumatol-
ogist’s assessment. Another study among GPs found that 
18% of patients with suspected IA was referred; though 
data on rheumatologists’ diagnoses were not provided.25 
Table 3 Multivariable logistic regression analyses with synovitis on joint examination as outcome
Model 1 Model 2
Derivation Derivation Validation
OR (95% CI) OR (95% CI) B OR (95% CI)
Male 1.7 (1.1 to 2.5) 1.7 (1.1 to 2.5) 0.517 1.7 (1.1 to 2.4)
Age (years) <40 (ref) 0–59.9 (ref) (ref) (ref)
40–59.9 1.5 (0.96 to 2.5) ≥60 2.1 (1.4 to 3.1) 0.750 2.1 (1.5 to 3.0)
≥60 2.9 (1.7 to 4.8)
Symptom duration (weeks) <6 3.8 (2.3 to 6.4) <6 3.6 (2.2 to 6.0) 1.279 3.4 (2.0 to 5.7)
6–11 1.7 (0.92 to 3.1) 6–51.9 2.2 (1.4 to 3.6) 0.797 1.9 (1.2 to 3.0)
12–51.9 2.9 (1.7 to 5.0) ≥52 (ref) (ref) (ref)
≥52 (ref)
Acute onset of symptoms* 1.0 (0.67 to 1.5) 0.99 (0.66 to 1.5) −0.015 1.0 (0.70 to 1.5)
Morning stiffness (minutes) >60 1.6 (0.88 to 2.9) >60 1.6 (0.91 to 2.9) 0.485 1.2 (0.62 to 2.3)
Number of painful joints 0 (ref) 0 (ref) (ref) (ref)
1–3 9.3 (1.1 to 78.2) 1–3 10.0 (1.2 to 83.4) 2.300 7.9 (0.91 to 68.6)
4–10 4.5 (0.53 to 37.6) ≥4 4.5 (0.54 to 37.1) 1.497 5.2 (0.61 to 45.1)
≥11 3.3 (0.39 to 28.4)
Number of patient-reported 
swollen joints
0 (ref) 0 (ref) (ref) (ref)
1–3 3.2 (1.6 to 6.4) ≥1 3.5 (1.9 to 6.6) 1.253 3.7 (1.9 to 7.0)
4–10 3.4 (1.7 to 7.0)
≥11 4.3 (1.9 to 10.0)
Difficulty with making a fist 1.6 (0.97 to 2.5) 1.6 (0.99 to 2.6) 0.467 1.4 (0.91 to 2.2)
Intercept −4.8 −4.6 −4.6
AUC 0.76
(0.71 to 0.80)
0.75
(0.70 to 7.79)
0.72
(0.68 to 0.77)
Model 1 includes categories of clinically applicable cut-offs; if within variables, several categories had similar regression coefficients, 
categories were pooled (model 2).
*Patients were asked to define onset of symptoms; either acute onset of symptoms or gradual onset of symptoms, see online supplementary 
appendix S1. Variables with p values <0.05 in univariable analysis in the derivation set were entered in multivariable regression analyses.
AUC, area under the receiver operating characteristic curve; B, beta.
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Guided by these scarce data obtained in GP practices, 
performance of the model was simulated with an esti-
mated prevalence of 20%.5 The intercept of the regres-
sion model was adjusted as described in King et al26 27 
and we plotted average estimated predicted probabilities 
against the regression and simplified risk score.
Statistical analyses were performed using Statistical 
Package for the Social Sciences (SPSS, V.23.0). P values 
<0.05 were considered significant.
Patient involvement
Patient research partners agreed with the pathway of care 
at EARC. They also provided feedback on the question-
naire, which was expanded in 2012 with two questions.
results
Patients
One thousand two hundred and eighty-eight patients 
in whom GPs were unsure about the presence of IA 
visited EARC between 2010 and 2015; of these, 41% had 
synovitis at joint examination. The frequency of inflam-
matory arthritis was stable throughout the study years 
(see online supplementary appendix S3). Baseline char-
acteristics of patients in both derivation and validation 
data set are presented in table 1.
Model derivation
In univariable analyses, male gender, age ≥60 years, 
symptom duration of <6 weeks, an acute onset of symp-
toms, morning stiffness >60 min, a low number of 
painful joints (1–3 joints), presence of patient-reported 
joint swelling (1–3 joints) and difficulty with making a 
fist were associated with the presence of IA in the deri-
vation data set (table 2). ‘Symptoms worst in the early 
morning’ was not associated with IA and therefore not 
included in multivariable analysis. Two multivariable 
models were created with categorised variables; first, a 
model with categories similar to the univariable analysis 
(table 3, model 1), and second a model pooling cate-
gories per variable with similar regression coefficients 
(table 3, model 2). Performing this second model in the 
derivation data set revealed that male gender, age ≥60 
years, symptom duration of <6 weeks, a low number of 
painful joints (1–3 joints), and presence of patient-re-
ported joint swelling were independently associated with 
the presence of IA (table 3). The AUC of model 2 was 
0.75 (95% CI 0.70 to 0.79) in the derivation dataset. In 
subanalysis, model 2 was repeated with a backward selec-
tion procedure, showing similar regression coefficients 
(see online supplementary appendix S4).
generation of a simplified rule
In order to facilitate usage in routine clinical practice, a 
simplified model was generated (see online supplemen-
tary appendix S5). The obtained regression coefficient of 
acute onset of symptoms in multivariable modelling was 
−0.015, yielding 0 points. Also after exclusion of this vari-
able, the regression coefficients of the other seven vari-
ables in the model did not change yielding similar points. 
This resulted in a simplified rule consisting of seven scored 
items and a total score ranging from 0 to 7.5 with corre-
sponding predicted risks (figure 1). Risks of IA predicted 
by the model as a function of the regression score (ie, the 
sum of the regression coefficients times the value of the 
corresponding covariates) are presented in figure 2A; as 
shown, simplification did not majorly affect the predicted 
risks. The calibration plot shows that predicted proba-
bilities correlated well with the observed proportions of 
patients with IA (see online supplementary appendix S6). 
The Hosmer-Lemeshow test for the derivation data set 
yielded a p value of 0.36. If cut-offs are required and a 
highly sensitive approach is preferred (>90% sensitivity), 
this is obtained by a cut-off score of ≥4. When a highly 
specific approach is preferred (>90% specificity), this 
Figure 1 The Clinical Arthritis RulE and corresponding predicted risks of the presence of inflammatory arthritis per 
score. Observed risks of current inflammatory arthritis were obtained by calculating the proportion of patients with a positive 
outcome (rheumatologist-confirmed synovitis) for each value of the risk score in the derivation data set.
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is obtained by a cut-off score of ≥6. Test characteristics 
for all cut-off points are presented in online  supple-
mentary appendix S7. The AUC of the simplified score, 
measuring discrimination, was 0.74 (95% CI 0.70 to 0.78; 
see online supplementary appendix S8).
Validation
The final multivariable model (model 2) was applied in 
the validation data set, revealing similar results (table 3). 
The AUC was 0.72 (95% CI 0.68 to 0.77). Figure 2A 
shows the predicted probabilities of the simplified rule 
are almost similar to those obtained in the derivation 
data. The AUC of the simplified rule was 0.71 (95% CI 
0.67 to 0.75) in the validation data set. The calibration 
plot is shown in online supplementary appendix S6; the 
Hosmer-Lemeshow test for the validation data set yielded 
a p value of 0.43.
simulation of accuracy in a setting with a lower prevalence of 
IA
In contrast to test characteristics, predicted probabil-
ities depend on the prior risk (ie, prevalence) of IA. 
The frequency of IA among primary care patients with 
GP-determined clinical suspicion of IA may be different 
than that observed in EARC. Based on observations in 
GP practices,5 25 a simulation was run for the regression 
and simplified score with a prevalence of inflammatory 
arthritis set at 20%. Estimated predicted probabilities for 
different scores of the multivariable model and simplified 
rule (in derivation and validation data sets) are presented 
in figure 2B.
Our simplified rule was implemented in a web applica-
tion that provides predictions on the presence of current 
IA for individual patients; a screenshot is presented 
in figure 3. The web application is accessible online at 
http:// caretool. eu/.
DIsCussIOn
GPs play a crucial role in the early identification of RA 
and often lack confidence in detecting joint synovitis.9 In 
an attempt to solve the contradiction between the need 
to refer very early and absence of evidence who must 
be referred, we provided an evidence-based and simple 
method to identify the presence of IA in patients in 
whom IA is suspected. This clinical rule helps to select 
patients to refer for additional investigations (laboratory 
or imaging) or to secondary care. Hence, the Clinical 
Arthritis RulE (CARE) could increase appropriateness of 
healthcare utilisation.
This study is different from studies that derived tools 
to facilitate triage of patients that have been referred to 
secondary or tertiary care15–17 as our study did not aim to 
prioritise patients that are already referred. In addition, 
we aimed to facilitate recognition of IA (as this would 
necessitate prompt referral to a rheumatologist) and did 
not perform a longitudinal study to predict development 
of specific diagnoses (eg, RA) later on. This explains why 
several factors were found to be associated with pres-
ence of IA that are not generally considered typical for 
RA (male gender, a low number of painful joints, a short 
symptom duration). GPs generally do well in identifying 
those at high risk for development of RA (ie, women 
with subacute smouldering polyarticular, symmetric 
complaints), and therefore we aimed this tool to assist 
Figure 2 The Clinical Arthritis RulE and presentation of the predicted probabilities of the presence of current inflammatory 
arthritis based on the regression model, and the simplified score as observed in the derivation and validation data sets (A), 
and estimated predicted probabilities in a simulation with a pretest probability (ie, prevalence) of inflammatory arthritis of 
20% (B). Predicted probabilities of the final multivariable logistic regression model, fitted in the derivation set as function of 
the regression score (ie, the sum of the regression coefficients times the value of the corresponding covariates (green line)). 
Furthermore, for each value of the simplified score, the mean predicted probability is plotted in the derivation and validation 
dataset (blue and orange dots).
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GPs in decision-making for more atypical or non-classical 
presentations of IA (eg, due to overlap of symptoms with 
other diagnoses) leading to doubt. Indeed, many of the 
patients that did not have synovitis at EARC had symptoms 
due to diagnoses that are characterised by longstanding 
or extensive joint pain (eg, osteoarthritis, fibromyalgia), 
explaining higher scores for a short symptom duration or 
a low number of symptomatic joints.
Adding other clinical variables might increase the 
discriminative ability of the model. Potential examples 
include the squeeze test of the metacarpophalangeal 
joints (although the diagnostic accuracy was shown to 
Figure 3 A stylised representation of the Clinical Arthritis RulE, to be used in patients in whom general practitioners (GPs) 
doubt about the presence of inflammatory arthritis. The web application that provides predictions on the predicted risk of 
inflammatory arthritis for individual patients as can be accessed at http://caretool.eu/.
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be only moderate28), information on family history or 
functional impairments. These items were not routinely 
collected before December 2015. Adding data on labo-
ratory investigations to our rule could potentially also 
increase its discriminative ability. However, our data do 
not permit us to evaluate this, as additional investigations 
were done afterwards and only in patients with synovitis 
at joint examination.
A strength of our EARC for the purpose of this study is 
that GPs in our region are familiar with the need for early 
referral and that regional healthcare logistics make rheu-
matology care rapidly available for patients with arthritis, 
with EARC as ultimate service for patients in whom GPs 
suspect (but are unsure about) IA. With the availability 
of EARC every week and lack of any waiting list for 
EARC, we assume a low number of patients not showing 
up at EARC despite being encouraged by their GP to 
visit EARC. As EARC serves as a unique bridge between 
primary and secondary care, its patients closely resemble 
the population GPs have contact with and have doubts 
about. Although EARC is successful in our region,11 23 this 
approach may be more difficult to implement in other 
centres or regions due to a shortage of rheumatologists, 
or long travelling distances to rheumatology outpatient 
clinics, and as such a different system is needed to aid GPs 
in identifying IA. This prompted us to derive a validated 
rule composed of clinical characteristics that could assist 
GPs in decision-making for more atypical or non-classical 
(but nevertheless suspect) presentations of IA, as classical 
presentations usually do not cause GPs concern.
GPs were discouraged (both by our local communica-
tion with GPs and according to national guidelines for 
GPs) to perform autoantibody testing.29 Autoantibody 
testing in primary care in this region was infrequent,5 
unlike in other parts of the world. Autoantibody testing 
may falsely reassure doctors and patients, especially when 
results are negative, and as such we believe a model based 
on clinical presentation is more appropriate to facilitate 
rapid referral.
Another strength is that we studied patients in whom 
the GPs have indicated a lack of confidence to identify 
the presence of synovitis. Patients with clinically obvious 
IA had early access to rheumatological care already. This 
may enhance the generalisability of the present data to 
the setting of doubt in primary care. Furthermore, the 
use of real-life observational data in our study may boost 
external validity of the results.
A disadvantage of our setting is that the data were not 
collected in primary care itself, but in a setting interme-
diary between primary and secondary care. Although 
musculoskeletal symptoms are a very common reason 
for consulting primary care, suspected IA is relatively 
unusual, and the average full-time GP diagnoses only one 
new patient with RA each year.30 Additionally, although 
EARC is easily accessible on a weekly basis, the exact 
number of patients that were referred but did not visit 
EARC is unknown. Validation in primary care is required. 
We studied ‘the difficult group’ of patients in whom GPs 
were uncertain of the presence of suspected IA. The prev-
alence of such patients in primary care may be higher 
and, as a consequence, the actual prevalence of IA among 
suspected IA patients may be lower than 41% in primary 
care. Since the post-test probabilities strongly depend on 
the prevalence (ie, pretest probability), a simulation was 
performed with an estimated prevalence of IA that was 
half of the prevalence as observed in our data (20%). The 
choice of 20% was based on the literature from primary 
care; although not much is known about suspected IA in 
primary care, two studies suggested a prevalence of IA 
among suspected patients of 18%–27%.5 25 We demon-
strated the predictive accuracy of the model using a simu-
lated prevalence of 20%. Because of the limitation that 
Figure 4 Flowchart of decision-making in patients with suspected early inflammatory arthritis (IA) based on clinical 
characteristics and the role of the Clinical Arthritis RulE (CARE). GPs, general practitioners.
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no other data are available on the prevalence of IA when 
GPs suspect IA, this estimated prevalence could be an 
overestimation. However, the observed data could also be 
an underestimation, as in our setting, GPs were instructed 
to refer patients with high suspicion/definite arthritis to 
the regular outpatient clinic. Further external validation 
in GP settings is therefore required.
GPs in our region are well informed about the impor-
tance of the early detection of IA, but the GPs in our 
region feel that their actual detection skills are not 
different from that of GPs elsewhere. However, if the 
detection skills of our GPs are different from that of GPs 
in other regions, a lower prevalence of IA (and therefore 
lower pretest probabilities) may be present. As a conse-
quence, the rule may yield lower post-test probabilities. 
This effect may have been dealt with in the simulation 
analysis but still external validation in primary care and 
preferably in different regions or countries is necessary.
We expect that our rule (CARE) might support GPs and 
other healthcare professionals in the decision-making 
process in patients with musculoskeletal symptoms in 
whom they suspect IA, regardless of the region. Of course, 
the consequences of an increased score will likely depend 
on the setting and relation with secondary care: it can 
either influence the decision to directly refer a patient or 
to first ask for additional laboratory tests (eg, acute phase 
reactants or autoantibodies; figure 4). A clinical decision 
aid may be of value to this end as well, as for most labo-
ratory investigations, the diagnostic accuracy depends on 
the prior risk. Using a simple clinical decision aid first 
may be more cost-effective than performing additional 
investigations in all patients in whom there is doubt about 
IA. Depending on the setting and consequences of a high 
score, either a sensitive method or a specific method may 
be preferred; for this reason, cut-offs for both situations 
are provided. The web application, also easily assessable 
by phone, facilitates implementation of CARE by GPs, 
physicians and other healthcare professionals such as 
physiotherapists in their daily work.
COnClusIOn
In conclusion, this study developed a clinical rule that 
supports the identification of patients suspected of having 
IA by physicians that feel insufficiently experienced in 
assessment of synovitis by joint examination. We hope the 
current data are a prelude to a data-driven method that 
supports GPs, physicians and other healthcare profes-
sionals in decision-making in patients with suspected 
early IA.
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